This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Janssen Sciences Ireland Unlimited Company. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: David Craig McGowan: Innovator in Immunomodulation
Introduction
David Craig McGowan is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of immunology, particularly in the development of novel therapeutic agents. His work focuses on enhancing the body's immune response to combat diseases.
Latest Patents
David Craig McGowan holds a patent for "Heterocyclic immunomodulators as PDL1 checkpoint inhibitor." This patent describes pyridinone-containing inhibitors of PD-L1, which are pharmaceutical compositions that include these compounds. The patent also outlines the chemical processes for preparing these compounds and their applications in treating infectious diseases and cancer. He has 1 patent to his name.
Career Highlights
David is currently employed at Janssen Sciences Ireland Unlimited Company, where he continues to advance his research in immunomodulation. His work at Janssen has positioned him at the forefront of innovative therapeutic development.
Collaborations
One of his notable collaborators is Edgar Jacoby, with whom he has worked on various projects related to immunotherapy.
Conclusion
David Craig McGowan's contributions to the field of immunology through his innovative patent and work at Janssen Sciences highlight his role as a key figure in advancing treatments for serious health conditions. His ongoing research promises to impact the future of immunotherapy significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile